Phase 2 Open-Label Study of Long-Term Safety, Tolerability, and Antiviral Activity of Rilpivirine in Antiretroviral-Naive Adolescents Living with HIV-1

Johan Lombaard, Francis Ssali, Puthanakit Thanyawee, Jan Fourie, Simon Vanveggel, Cornelia Linthicum, Veerle Van Eygen, Rodica Van Solingen-Ristea, Johan Lombaard, Francis Ssali, Puthanakit Thanyawee, Jan Fourie, Simon Vanveggel, Cornelia Linthicum, Veerle Van Eygen, Rodica Van Solingen-Ristea

Abstract

This phase 2 study investigated long-term safety and efficacy of rilpivirine (RPV) plus two investigator-selected nucleos(t)ide reverse transcriptase inhibitors (NRTIs) in HIV-1-infected antiviral therapy-naive adolescents. Participants (≥12 to <18 years of age) were treated with RPV at 25 mg once daily (q.d.) plus 2 NRTIs and entered the treatment extension period for up to 240 weeks, with visits every 3 months. Long-term safety (analysis of adverse events [AEs] and laboratory results), efficacy (virologic response and outcome for patients with viral loads of <50 and <400 by time to loss of virologic response [TLOVR] and FDA Snapshot methods, as well as CD4+ cell count), and adherence (by pill count) for up to 240 weeks are presented. Twenty-four of 36 participants entered the treatment extension period, and 21 completed week 240. At week 240, a viral load of <50 copies/mL was achieved by 14/32 (43.8%) participants; virologic response by TLOVR was higher in participants with a baseline viral load of ≤100,000 copies/mL (48.0%) versus a viral load of >100,000 copies/mL (28.6%). By FDA Snapshot, a viral load of <50 copies/mL at week 240 was found in 53.1% (17/32) of participants with a baseline viral load of ≤100,000 copies/mL. Higher response was observed in participants with adherence of >95% and a baseline viral load of ≤100,000 copies/mL. Through week 240, 16/32 participants (50.0%) experienced virologic failure, including seven who developed treatment-emergent RPV resistance-associated mutations (RAMs [frequently E138K]): all 7 had ≥1 treatment-emergent NRTI RAM. No serious AEs after week 48, no discontinuations due to AEs between week 48 and week 240, and no new safety signals were observed. RPV did not affect pubertal development or adolescent growth. At the 5-year follow-up, efficacy was low in adolescents, particularly those with poor adherence and/or a high baseline viral load of >100,000 copies/mL. To limit the risk of virologic failure, RPV is restricted to patients with a baseline VL of ≤100,000 copies/mL in most countries. In addition, adequate treatment adherence to RPV treatment is imperative for long-term viral suppression and should be emphasized in the management of adolescents living with HIV. RPV exhibited a favorable long-term safety profile for adolescents living with HIV-1 with adequate adherence. (This study has been registered at ClinicalTrials.gov under identifier NCT00799864.).

Keywords: HIV-1; adolescents; antiretroviral therapy; efficacy; rilpivirine; safety.

Conflict of interest statement

The authors declare a conflict of interest. This study was funded by Janssen Research & Development, LLC. VVE and RVS are employees of Janssen Research & Development, Belgium, and may hold stock/stock options in Johnson & Johnson; CL is an employee of Janssen Vaccines AG, Bern, Switzerland and may hold stock/stock options in Johnson & Johnson.

Figures

FIG 1
FIG 1
Study design. HIV, human immunodeficiency virus; N(t)RTIs, nucleos(t)ide analogue reverse transcriptase inhibitor; PK, pharmacokinetics; q.d., once daily; RPV, rilpivirine.
FIG 2
FIG 2
Virologic response (

References

    1. Della Negra M, Carvalho AP, De Aquino MZ, Pinto JA, Da Silva MTN, Andreatta KN, Graham B, Liu Y-P, Quirk EK. 2015. Long-term efficacy and safety of tenofovir disoproxil fumarate in HIV-1-infected adolescents failing antiretroviral therapy: the final results of study GS-US-104-0321. Pediatr Infect Dis J 34:398–405. 10.1097/INF.0000000000000649.
    1. Mutwa PR, Boer KR, Rusine J, Muganga N, Tuyishimire D, Schuurman R, Reiss P, Lange JMA, Geelen SPM. 2014. Long-term effectiveness of combination antiretroviral therapy and prevalence of HIV drug resistance in HIV-1-infected children and adolescents in Rwanda. Pediatr Infect Dis J 33:63–69. 10.1097/INF.0b013e31829e6b9f.
    1. Murphy DA, Wilson CM, Durako SJ, Muenz LR, Belzer M, Adolescent Medicine HIV/AIDS Research Network. 2001. Adolescent Medicine HIVARN. Antiretroviral medication adherence among the REACH HIV-infected adolescent cohort in the USA. AIDS Care 13:27–40. 10.1080/09540120020018161.
    1. Marshall WA, Tanner JM. 1970. Variations in the pattern of pubertal changes in boys. Arch Dis Child 45:13–23. 10.1136/adc.45.239.13.
    1. Murphy DA, Sarr M, Durako SJ, Moscicki AB, Wilson CM, Muenz LR, Adolescent Medicine HIV/AIDS Research Network. 2003. Barriers to HAART adherence among human immunodeficiency virus-infected adolescents. Arch Pediatr Adolesc Med 157:249–255. 10.1001/archpedi.157.3.249.
    1. Cohen CJ, Molina J-M, Cahn P, Clotet B, Fourie J, Grinsztejn B, Wu H, Johnson MA, Saag M, Supparatpinyo K, Crauwels H, Lefebvre E, Rimsky LT, Vanveggel S, Williams P, Boven K. 2012. Efficacy and safety of rilpivirine (TMC278) versus efavirenz at 48 weeks in treatment-naive HIV-1-infected patients: pooled results from the phase 3 double-blind randomized ECHO and THRIVE trials. J Acquired Immune Deficiency Syndromes 60:33–42. 10.1097/QAI.0b013e31824d006e.
    1. Cohen CJ, Molina J-M, Cassetti I, Chetchotisakd P, Lazzarin A, Orkin C, Rhame F, Stellbrink H-J, Li T, Crauwels H, Rimsky L, Vanveggel S, Williams P, Boven K. 2013. Week 96 efficacy and safety of rilpivirine in treatment-naive, HIV-1 patients in two phase III randomized trials. AIDS 27:939–950. 10.1097/QAD.0b013e32835cee6e.
    1. Molina JM, Clumeck N, Redant K, Rimsky L, Vanveggel S, Stevens M. 2013. Rilpivirine vs. efavirenz in HIV-1 patients with baseline viral load 100,000 copies/ml or less: week 48 phase III analysis. AIDS 27:889–897. 10.1097/QAD.0b013e32835e1554.
    1. Lombaard J, Bunupuradah T, Flynn PM, Ramapuram J, Ssali F, Crauwels H, Hoogstoel A, Van Eygen V, Stevens M. 2016. Rilpivirine as a treatment for HIV-infected antiretroviral-naive adolescents: week 48 safety, efficacy, virology and pharmacokinetics. Pediatr Infect Dis J 35:1215–1221. 10.1097/INF.0000000000001275.
    1. Lombaard J, Bunupuradah T, Flynn P, Ramapuram J, Ssali F, Vanveggel S, Williams P, Yarnall W, Stevens M. 2014. Safety and efficacy of a rilpivirine-based regimen in HIV-infected treatment-naive adolescents: week 24 primary analysis of the PAINT phase II trial, abstr O_05. 6th Int Workshop HIV Pediatr. .
    1. Okatch H, Beiter K, Eby J, Chapman J, Marukutira T, Tshume O, Matshaba M, Anabwani GM, Gross R, Lowenthal E. 2016. Brief Report. Apparent antiretroviral overadherence by pill count is associated with HIV treatment failure in adolescents. J Acquir Immune Defic Syndr 72:542–545. 10.1097/QAI.0000000000000994.
    1. McHugh G, Simms V, Dauya E, Bandason T, Mujuru H, Munyati S, Weiss H, Rehman AM, Odland J, Ferrand. 2018. Targeting the third “90”: are children and adolescents slipping through the net? 22nd Int AIDS Conf, Amsterdam, the Netherlands, 23 to 27 July 2018. .
    1. Ryscavage P, Anderson EJ, Sutton SH, Reddy S, Taiwo B. 2011. Clinical outcomes of adolescents and young adults in adult HIV care. J Acquir Immune Defic Syndr 58:193–197. 10.1097/QAI.0b013e31822d7564.
    1. Sithole Z, Mbizvo E, Chonzi P, Mungati M, Juru TP, Shambira G, Gombe NT, Tshimanga M. 2018. Virological failure among adolescents on ART, Harare City, 2017—a case-control study. BMC Infect Dis 18:469. 10.1186/s12879-018-3372-6.
    1. McKinney RE, Rodman J, Hu C, Britto P, Hughes M, Smith ME, Serchuck LK, Kraimer J, Ortiz AA, Flynn P, Yogev R, Spector S, Draper L, Tran P, Scites M, Dickover R, Weinberg A, Cunningham C, Abrams E, Blum MR, Chittick GE, Reynolds L, Rathore M, Pediatric AIDS Clinical Trials Group Protocol P1021 Study Team. 2007. Long-term safety and efficacy of a once-daily regimen of emtricitabine, didanosine, and efavirenz in HIV-infected, therapy-naive children and adolescents: Pediatric AIDS Clinical Trials Group Protocol P1021. Pediatrics 120:e416-23. 10.1542/peds.2006-0925.
    1. Viani RM, Ruel T, Alvero C, Fenton T, Acosta EP, Hazra R, Townley E, Palumbo P, Buchanan AM, Vavro C, Singh R, Graham B, Anthony P, George K, Wiznia A, Heckman B, Popson S, Sise T, Hergott K, Myers K, Rodriguez CA, Emmanuel PJ, Casey D, Wara D, Tilton N, Aziz M, McNichols M, Logan L, Sirisanthana V, Aurpibul L, Kosachunhanan N, Jensen J, Williams R, Qureshi T, Dobroszycki J, Huh H, Reinoso F, Rana S, Houston P, Mengistab M, Burchett SK, Karthas N, Kneut C, P1093 Study Team. 2020. Long-term safety and efficacy of dolutegravir in treatment-experienced adolescents with human immunodeficiency virus infection: results of the IMPAACT P1093 study. J Pediatr Infect Dis Soc 9:159–165. 10.1093/jpids/piy139.
    1. Puthanakit T, Aurpibul L, Oberdorfer P, Akarathum N, Kanjanavanit S, Wannarit P, Sirisanthana T, Sirisanthana V. 2007. Sustained immunologic and virologic efficacy after four years of highly active antiretroviral therapy in human immunodeficiency virus infected children in Thailand. Pediatr Infect Dis J 26:953–956. 10.1097/INF.0b013e318125720a.
    1. Salazar JC, Cahn P, Della Negra M, De Aquino MZ, Robinson PA, Jelaska A, Mikl J. 2014. Efficacy and safety of tipranavir coadministered with ritonavir in HIV-1-infected children and adolescents: 5 years of experience. Pediatr Infect Dis J 33:396–400. 10.1097/INF.0000000000000038.
    1. World Health Organization. 2018. The 2018 Optimal Formulary and Limited Use List for Pediatric ARVs. .
    1. World Health Organization. 2018. AIDS Free Framework to accelerate paediatric and adolescent HIV treatment. .
    1. Marshall WA, Tanner JM. 1969. Variations in pattern of pubertal changes in girls. Arch Dis Child 44:291–303. 10.1136/adc.44.235.291.
    1. Azijn H, Tirry I, Vingerhoets J, de Béthune M-P, Kraus G, Boven K, Jochmans D, Van Craenenbroeck E, Picchio G, Rimsky LT. 2010. TMC278, a next-generation nonnucleoside reverse transcriptase inhibitor (NNRTI), active against wild-type and NNRTI-resistant HIV-1. Antimicrob Agents Chemother 54:718–727. 10.1128/AAC.00986-09.
    1. Rimsky L, Vingerhoets J, Van Eygen V, Eron J, Clotet B, Hoogstoel A, Boven K, Picchio G. 2012. Genotypic and phenotypic characterization of HIV-1 isolates obtained from patients on rilpivirine therapy experiencing virologic failure in the phase 3 ECHO and THRIVE studies: 48-week analysis. J Acquir Immune Defic Syndr 59:39–46. 10.1097/QAI.0b013e31823df4da.
    1. Johnson VA, Brun-Vezinet F, Clotet B, Kuritzkes DR, Pillay D, Schapiro JM, Richman DD. 2006. Update of the drug resistance mutations in HIV-1: Fall 2006. Top HIV Med 14:125–130.
    1. Vingerhoets J, Rimsky L, Van Eygen V, Nijs S, Vanveggel S, Boven K, Picchio G. 2013. Pre-existing mutations in the rilpivirine phase III trials ECHO and THRIVE: prevalence and impact on virological response. Antivir Ther 18:253–256. 10.3851/IMP2358.
    1. US Department of Health and Human Services Food and Drug Administration Center for Drug Evaluation and Research (CDER). November 2015. Guidance for Industry. Human immunodeficiency virus-1 infection: developing antiretroviral drugs for treatment. . Accessed 13 March 2020.
    1. US Department of Health and Human Services Food and Drug Administration Center for Drug Evaluation and Research (CDER). October 2002. Guidance for Industry. Antiretroviral drugs using plasma HIV RNA measurements—clinical considerations for accelerated and traditional approval. . Accessed March 2019.
    1. Eron JJ, Orkin C, Gallant J, Molina J-M, Negredo E, Antinori A, Mills A, Reynes J, Van Landuyt E, Lathouwers E, Hufkens V, Jezorwski J, Vanveggel S, Opsomer M. 2018. A week-48 randomized phase-3 trial of darunavir/cobicistat/emtricitabine/tenofovir alafenamide in treatment-naive HIV-1 patients. AIDS 32:1431–1442. 10.1097/QAD.0000000000001817.

Source: PubMed

Sponsors and Collaborators

Medical Conditions

Drug Interventions

3
Subscribe